CoChat
Cited by 47

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral

Bellcross, Cecelia A., Leadbetter, Steven, Alford, Sharon Hensley, Peipins, Lucy A. · 2013 · Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: In 2005, the United States Preventive Services Task Force (USPSTF) released guidelines which outlined specific family history patterns associated with an increased risk for BRCA1/2 mutations, and recommended at-risk individuals be referred for genetic counseling and evaluation for BRCA testing. The purpose of this study was to assess the prevalence of individuals with a USPSTF increased-risk family history pattern, the frequency with which specific patterns were met, and resulting healthcare actions among women from the Henry Ford Health System. Methods: As part of a study evaluating ovarian cancer risk perception and screening, 2,524 randomly selected participants completed a detailed interview (response rate 76%) from an initial eligible cohort of 16,720 women. Results: Approximately 6% of participants had a family history fulfilling one or more of the USPSTF patterns. Although 90% of these women had shared their family history with their provider, less than 20% had been referred for genetic counseling and only 8% had undergone genetic testing. Caucasian women with higher income and education levels were more likely to receive referrals. Among the 95 participants in the total study cohort who reported BRCA testing, 78% did not have a family history that met one of the USPSTF patterns. Conclusions: These results suggest a higher prevalence of women with an increased-risk family history than originally predicted by the USPSTF, and lack of provider recognition and referral for genetic services. Impact: Improvements in healthcare infrastructure and clinician education will be required to realize population level benefits from BRCA genetic counseling and testing. Cancer Epidemiol Biomarkers Prev; 22(4); 728–35. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-12-1280

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 32

  1. Anglian Breast Cancer Study Group, 2000, Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases, Br J Cancer, 83, 1301, 10.1054/bjoc.2000.1407 · DOI · Paper page
  2. Risch, 2006, Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada, J Natl Cancer Inst, 98, 1694, 10.1093/jnci/djj465 · DOI · Paper page
  3. Pal, 2005, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 104, 2807, 10.1002/cncr.21536 · DOI · Paper page
  4. Nelson, 2005, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services USPSTF, Ann Intern Med, 143, 362, 10.7326/0003-4819-143-5-200509060-00012 · DOI · Paper page
  5. Isern, 2008, Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer, Eur J Surg Oncol, 34, 1148, 10.1016/j.ejso.2008.03.002 · DOI
  6. Kauff, 2008, Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study, J Clin Oncol, 26, 1331, 10.1200/JCO.2007.13.9626 · DOI · Paper page
  7. Saslow, 2007, American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography, CA Cancer J Clin, 57, 75, 10.3322/canjclin.57.2.75 · DOI · Paper page
  8. Kurian, 2010, Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers, J Clin Oncol, 28, 222, 10.1200/JCO.2009.22.7991 · DOI · Paper page
  9. Warner, 2011, Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging, J Clin Oncol, 29, 1664, 10.1200/JCO.2009.27.0835 · DOI · Paper page
  10. Kaas, 2010, Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer, Ann Surg, 251, 488, 10.1097/SLA.0b013e3181c3c36d · DOI
  11. Domchek, 2006, Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study, Lancet Oncol, 7, 223, 10.1016/S1470-2045(06)70585-X · DOI · Paper page
  12. Warner, 2008, Systematic review: using magnetic resonance imaging to screen women at high-risk for breast cancer, Ann Intern Med, 148, 671, 10.7326/0003-4819-148-9-200805060-00007 · DOI · Paper page
  13. United States Preventive Services Task Force, 2005, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement, Ann Intern Med, 143, 355, 10.7326/0003-4819-143-5-200509060-00011 · DOI · Paper page
  14. Levy, 2009, Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization, J Gen Intern Med, 24, 822, 10.1007/s11606-009-1009-6 · DOI · Paper page
  15. Hall, 2008, Population prevalence of first-degree family history of breast and ovarian cancer in the United States: Implications for genetic testing, Open Health Serv Policy J, 1, 38
  16. Palomaki, 2006, Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women, Genet Med, 8, 161, 10.1097/01.gim.0000204458.84988.f2 · doi:10.1097/01.gim.0000204458.84988.f2
  17. McClain, 2008, Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women, Fam Cancer, 7, 341, 10.1007/s10689-008-9188-6 · doi:10.1007/s10689-008-9188-6
  18. Johnson, 2005, Genomics–the perfect information-seeking research problem, J Health Commun, 10, 323, 10.1080/10810730590950048 · DOI
  19. Bellcross, 2011, Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians, Am J Prev Med, 40, 61, 10.1016/j.amepre.2010.09.027 · DOI · Paper page
  20. Trivers, 2011, Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study, Cancer, 117, 5334, 10.1002/cncr.26166 · DOI · Paper page
  21. Petrucelli, 2010, Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2, Genet Med, 12, 245, 10.1097/GIM.0b013e3181d38f2f · DOI · Paper page
  22. Steiner, 2008, Assessing breast cancer risk in women, Am Fam Phys, 78, 1361
  23. Irshad, 2011, Therapeutic potential of PARP inhibitors for metastatic breast cancer, Expert Rev Anticancer Ther, 11, 1243, 10.1586/era.11.52 · DOI
  24. ACOG Committee on Practice Bulletins, 2009, Hereditary breast and ovarian cancer syndrome, Gynecol Oncol, 113, 6, 10.1016/j.ygyno.2009.02.017 · DOI
  25. Katapodi, 2004, Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review, Prev Med, 38, 388, 10.1016/j.ypmed.2003.11.012 · DOI · Paper page
  26. Dancyger, 2011, Communicating BRCA1/2 genetic test results within the family: a qualitative analysis, Psychol Health, 26, 1018, 10.1080/08870446.2010.525640 · DOI
  27. Kenen, 2004, We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC), Psychooncology, 13, 335, 10.1002/pon.745 · DOI
  28. Koehly, 2009, Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions, Am J Public Health, 99, 2203, 10.2105/AJPH.2008.154096 · DOI
  29. Mai, 2011, Confirmation of family cancer history reported in a population-based survey, J Natl Cancer Inst, 103, 788, 10.1093/jnci/djr114 · DOI
  30. Murff, 2004, Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history, JAMA, 292, 1480, 10.1001/jama.292.12.1480 · DOI · Paper page
  31. Ziogas, 2003, Validation of family history data in cancer family registries, Am J Prev Med, 24, 190, 10.1016/S0749-3797(02)00593-7 · DOI · Paper page
  32. 2011, Cancer survivors–United States, 2007, MMWR Morb Mortal Wkly Rep, 60, 269

Cited by

See all 47

Metadata

Authors
Bellcross, C. A., Leadbetter, S., Alford, S. H., & Peipins, L. A.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2013-04-01
Volume
22
Issue
4
Pages
728-735
ISSN
  • 1055-9965
  • 1538-7755
Cited by
47
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral. https://app.cochat.ai/papers/10.1158/1055-9965.epi-12-1280
The paper
Bellcross, C. A., Leadbetter, S., Alford, S. H., & Peipins, L. A. (2013). Prevalence and Healthcare Actions of Women in a Large Health System with a Family History Meeting the 2005 USPSTF Recommendation for BRCA Genetic Counseling Referral. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-12-1280

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.